GlobalData on MSN2d
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase IIIUK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...
GlobalData on MSN13d
Persica’s antibiotic-based drug alleviates lower back pain in Phase Ib trialPersica's antibiotic-based drug could benefit patients with chronic lower back pain who are suffering from an infection in ...
The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...
Clinical Trials Arena on MSN10d
Merck KGaA’s lupus drug fails in SLE cohort of Phase II trialMerck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...
The single-dose vial presentation has marketing authorization from the national drugs regulator—Central Drugs Standard ...
While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...
Glasgow, Scotland Wednesday, March 19, 2025, 09:00 Hrs [IST] ...
Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing Alzheimer's symptoms by 50%.
Scientists have developed a revolutionary AI ‘fingerprint’ technology that can accurately show how cancer cells respond to new drugs, by simply observing changes to their shape. The new technology, ...
On Monday, Novo Nordisk A/S (NYSE:NVO) announced headline results from the REDEFINE 2 phase 3 ... REDEFINE 2 trial was based on a flexible protocol, allowing patients to modify their dosing throughout ...
Oxford BioTherapeutics (OBT) has lined up another big pharma partner for its drug discovery platform, agreeing to work with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback